These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31544037)

  • 1. Effect of diluted povidone iodine in adenoviral keratoconjunctivitis on the rate of subepithelial corneal infiltrates.
    Altan-Yaycioglu R; Sahinoglu-Keskek N; Canan H; Coban-Karatas M; Ulas B
    Int J Ophthalmol; 2019; 12(9):1420-1425. PubMed ID: 31544037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of povidone-iodine 2% eye drops in the treatment of adenoviral keratoconjunctivitis.
    Soleimani M; Tabatabaei SA; Mirzaei A; Esfandiari A; Soleymanzadeh M; Sadeghi R; Rad AH
    Oman J Ophthalmol; 2023; 16(1):69-74. PubMed ID: 37007229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of adenoviral keratoconjunctivitis with a combination of povidone-iodine 1.0% and dexamethasone 0.1% drops: a clinical prospective controlled randomized study.
    Kovalyuk N; Kaiserman I; Mimouni M; Cohen O; Levartovsky S; Sherbany H; Mandelboim M
    Acta Ophthalmol; 2017 Dec; 95(8):e686-e692. PubMed ID: 28342227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison between the Efficacy and Tolerability of Polyvinylpyrrolidone-Iodine Eye Drops 0.6% and 1% in Adenoviral Keratoconjunctivitis: A Randomized Clinical Trial.
    Makateb A; Soleymanzadeh M; Soleiman-Meigooni S; Asgari A; Etemadi MR; Mafi AR; Mohammadi N
    J Curr Ophthalmol; 2023; 35(4):337-344. PubMed ID: 39281394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of polyvinylpyrrolidone-iodine 0.6% treatment in adenoviral keratoconjunctivitis: a Prospective Randomized Controlled Study.
    Ricciardelli G; Giannaccare G; Di Zazzo A; Coassin M; Scorcia V; Romano MR; Allegrini D; Cennamo M; Antonini M; Bernabei F; Morelli A; Mencucci R
    Eye (Lond); 2022 Jan; 36(1):160-166. PubMed ID: 33654316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A treatment protocol for minimizing duration and complications of adenoviral epidemic keratoconjunctivitis.
    Kulkarni C; Ballal K
    Taiwan J Ophthalmol; 2020; 10(4):269-277. PubMed ID: 33437600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Povidone iodine in the treatment of adenoviral conjunctivitis in infants.
    Özen Tunay Z; Ozdemir O; Petricli IS
    Cutan Ocul Toxicol; 2015 Mar; 34(1):12-5. PubMed ID: 24678746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Relationship between Clinical Findings and Viral Load in Adenoviral Keratoconjunctivitis.
    Isik P; Harbiyeli II; Ozturk G; Erdem E; Yagmur M; Yarkin F
    Jpn J Infect Dis; 2022 Nov; 75(6):592-596. PubMed ID: 35908877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Adenoviral Keratoconjunctivitis: Challenges and Solutions.
    Labib BA; Minhas BK; Chigbu DI
    Clin Ophthalmol; 2020; 14():837-852. PubMed ID: 32256043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of topical regimen for adenoviral kearoconjunctivitis by 0.1% fluorometholone with and without polyvinyl alcohol iodine.
    Matsuura K; Terasaka Y; Miyazaki D; Shimizu Y; Inoue Y
    Jpn J Ophthalmol; 2021 Jan; 65(1):107-114. PubMed ID: 33241466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the impact of persistent subepithelial corneal infiltrations on the visual performance and corneal optical quality after epidemic keratoconjunctivitis.
    Aydin Kurna S; Altun A; Oflaz A; Karatay Arsan A
    Acta Ophthalmol; 2015 Jun; 93(4):377-82. PubMed ID: 25043311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclosporin A eye drop and subepithelial adenoviral keratoconjunctivitis infiltrates.
    Zghal I; Fekih O; Zgolli HM; Chargui S; Malek I; Nacef L
    Tunis Med; 2019 May; 97(5):639-643. PubMed ID: 31729734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical treatment of acute adenoviral keratoconjunctivitis with 0.2% cidofovir and 1% cyclosporine: a controlled clinical pilot study.
    Hillenkamp J; Reinhard T; Ross RS; Böhringer D; Cartsburg O; Roggendorf M; De Clercq E; Godehardt E; Sundmacher R
    Arch Ophthalmol; 2001 Oct; 119(10):1487-91. PubMed ID: 11594949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subepithelial infiltrates associated to viral keratoconjunctivitis following photorefractive keratectomy.
    Arcieri ES; Arcieri RS; França ET; Rocha FJ
    Eye (Lond); 2004 Oct; 18(10):1010-2. PubMed ID: 15094736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Treatment Models for Adenoviral Keratoconjunctivitis in the Childhood Population.
    Bekmez S; Eris E
    Ocul Immunol Inflamm; 2021 Nov; 29(7-8):1627-1632. PubMed ID: 32643975
    [No Abstract]   [Full Text] [Related]  

  • 16. The effects of cidofovir 1% with and without cyclosporin a 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study.
    Hillenkamp J; Reinhard T; Ross RS; Böhringer D; Cartsburg O; Roggendorf M; De Clercq E; Godehardt E; Sundmacher R
    Ophthalmology; 2002 May; 109(5):845-50. PubMed ID: 11986086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review and meta-analysis on the efficacy of topical povidone iodine in adenoviral conjunctivitis.
    González Martín-Moro J; Zarallo-Gallardo J; Guzmán-Almagro E; Antón Rodríguez C
    Cont Lens Anterior Eye; 2023 Oct; 46(5):101873. PubMed ID: 37380515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human adenoviral type 54 keratoconjunctivitis accompanied by stellate keratitis and keratic precipitates: two cases.
    Matsuura K; Terasaka Y; Uchio E; Saeki Y; Fujimoto T; Hanaoka N; Miyazaki D; Inoue Y
    BMC Ophthalmol; 2019 Jan; 19(1):7. PubMed ID: 30616635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenoviral keratoconjunctivitis in a tertiary care eye clinic.
    Butt AL; Chodosh J
    Cornea; 2006 Feb; 25(2):199-202. PubMed ID: 16371782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of a one-time, in-office administration of 5% povidone-iodine in the treatment of adenoviral conjunctivitis: The Reducing Adenoviral Patient Infected Days (RAPID) study.
    Shorter E; Whiteside M; Harthan J; Margolis MS; Hartwick AT; Johnson S; Migneco M; Morettin C; Olson CK; Huecker J; Than T; Gordon MO
    Ocul Surf; 2019 Oct; 17(4):828-832. PubMed ID: 31401340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.